The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

VI.a

Pulmonary embolism - Venous thrombosis/thromboembolism

Publications

Montani D, Bertoletti L, Chaumais MC, Perrin S, Fabre D, Chaouat A, Jaïs X, Simonneau G, Humbert M

Chronic thromboembolic pulmonary hypertension complicating long-term cyproterone acetate therapy.

European respiratory review : an official journal of the European Respiratory Society. 2014;23(132):260-3

Gourbil M, Grandvuillemin A, Beyens MN, Massy N, Gras V, D'Amico A, Miremont-Salamé G, Petitpain N, French Network of Regional Pharmacovigilance Centres

Thromboembolic events in women exposed to hormonal contraception or cyproterone acetate in 2012: a cross-sectional observational study in 30 French public hospitals.

Drug safety. 2014;37(4):269-82

Vasilakis-Scaramozza C, Jick H

Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives.

Lancet (London, England). 2001;358(9291):1427-9